Statement of Comprehensive Income

Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

AbbVie Inc., consolidated statement of comprehensive income

US$ in millions

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net earnings	4,286)	4,873)	11,845)	11,549)	4,622)
Foreign currency translation adjustments, net of tax	(1,008)	407)	(943)	(1,153)	1,511)
Net investment hedging activities, net of tax	484)	(399)	555)	699)	(799)
Pension and post-employment benefits, net of tax	824)	(30)	1,088)	521)	(102)
Cash flow hedging activities, net of tax	80)	(84)	—)	151)	(131)
Other comprehensive income (loss)	380)	(106)	700)	218)	479)
Comprehensive income	4,666)	4,767)	12,545)	11,767)	5,101)
Comprehensive income attributable to noncontrolling interest	(8)	(10)	(9)	(7)	(6)
Comprehensive income attributable to AbbVie Inc.	4,658)	4,757)	12,536)	11,760)	5,095)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Comprehensive income item	Description	The company
Net earnings attributable to AbbVie Inc.	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	AbbVie Inc. net earnings attributable to AbbVie Inc. decreased from 2022 to 2023 and from 2023 to 2024.
Comprehensive income attributable to AbbVie Inc.	Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners.	AbbVie Inc. comprehensive income attributable to AbbVie Inc. decreased from 2022 to 2023 and from 2023 to 2024.

AbbVie Inc. (NYSE:ABBV)

Statement of Comprehensive Income